// App-Quantinova.ai

PO1728 : Low- vs. Standard-Dose Rituximab for Induction and Maintenance Treatment of ANCA-Associated Vasculitis in Elderly Patients: A Single-Centre Observational Study

Researchers

Presenter

  • Rehman Shams Ur

Principal Investigators

  • Metraiah Elhakem

  • Kidder Dana

Medical Centers

  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Oraprine

  • Rituximab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved